Clinical implications of hedgehog signaling pathway inhibitors
Hailan Liu, Dongsheng Gu, Jingwu Xie
Wells Center for Pediatric Research, Division of Hematology and Oncology, Department of Pediatrics, Indiana University Simon Cancer Center, Indiana University, Indianapolis, Indiana 46202, USA.jinxie@ iupui.edu.
[Abstract] Hedgehog was first described in Drosophila melanogaster by the Nobel laureates Eric Wieschaus and Christiane Nüsslein-Volhard. The hedgehog (Hh) pathway is a major regulator of cell differentiation, proliferation, tissue polarity, stem cell maintenance, and carcinogenesis. The first link of Hh signaling to cancer was established through studies of a rare familial disease, Gorlin syndrome, in 1996. Follow-up studies revealed activation of this pathway in basal cell carcinoma, medulloblastoma and, leukemia as well as in gastrointestinal, lung, ovarian, breast, and prostate cancer. Targeted inhibition of Hh signaling is now believed to be effective in the treatment and prevention of human cancer. The discovery and synthesis of specific inhibitors for this pathway are even more exciting. In this review, we summarize major advances in the understanding of Hh signaling pathway activation in human cancer, mouse models for studying Hh-mediated carcinogenesis, the roles of Hh signaling in tumor development and metastasis, antagonists for Hh signaling and their clinical implications.
Chinese Journal of Cancer 2011, Volume: 30, Issue 1, Page: 13-26
[ PDF Full-text
[Google Scholar]Cite this article
Hailan Liu, Dongsheng Gu, Jingwu Xie. Clinical implications of hedgehog signaling pathway inhibitors. Chin J Cancer. 2011, 30(1):13-26. doi:10.5732/cjc.010.10540